AUG 14, 2018 11:40 PM PDT

Using Arsenic to Enhance Cancer Therapies Beyond Leukemia

Arsenic is anecdotally known to many as a poison, but it has historically been a potent chemotherapy agent.  Chemotherapies are basically controlled poisons; it is not so far-fetched to think of arsenic in these terms.  Originally used to treat leukemia in the nineteenth century, known as Fowler’s solution, arsenic continues to be investigated and used in conjunction with all-trans retinoic acid (ATRA) for the treatment and cure of Acute Promyelocytic Leukemia (APL).  Specifically, arsenic trioxide (ATO) is the active component needed to promote the anti-leukemic process in the body.  ATO acts on APL by destroying the main fusion protein called PML-RARα which is the disease driving genetic change causing the arrest of myelocytic cell differentiation.  Myelocytic cells need retinoic acid, or vitamin A, to continue developing into mature neutrophils which is why ATRA was used in the first place. 

A recent study published in Nature Communications outlines how ATO and ATRA together target an oncogenic signaling regulator called Pin1.  Pin1 activity is documented in multiple cancers besides leukemia including breast and liver solid tumors.  ATO has been found to degrade Pin1 and ATRA controls the cell’s ability to take up ATO when it is in the body.    

This is an emerging area of research because solid tumors are challenging to target; tumors are often found to utilize multiple activation pathways to remain viable and support their rapid growth.  Blocking one pathway may not work but finding the target that drives a multitude of signaling mechanisms, like in the case of Pin1, provides promise.  ATO and ATRA together have been proven safe at clinical doses and inhibited triple negative breast cancer cells as well as other tumor initiating cells in animal models. 

In vivo studies and clinically relevant data have demonstrated the viability and efficacy of using arsenic in conjunction with other therapeutic agents, like in the case of ATO-ATRA and APL.  Because this combination was found to impede further tumor growth via tumor initiating cells, the tumor’s normal renewal and progression process is disrupted.  In fact, the authors found that Pin1 is “highly enriched” in breast tumor initiating cells and propose further study on whether Pin1 inhibitor drugs could target these specific breast tumor cells.

Sources: Nature Communications, Pathology Outlines, Nature Medicine, Journals of Hematology & Oncology,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JUL 17, 2018
Cancer
JUL 17, 2018
New Small Cell Lung Cancer Subtype Identified
A new subtype of small cell lung cancer is reported to account for potentially 20% of small cell lung cancers diagnosed; it has unique molecular biomarkers and regulatory mechanisms....
JUL 24, 2018
Cancer
JUL 24, 2018
Transfection, Transduction, and CRISPR...Oh My
CRISPR gene editing came about based on transfection and transduction type models of genetic transfer. There is potential for it to revolutionize gene editing but are there dangers lurking?...
SEP 05, 2018
Videos
SEP 05, 2018
Why Glioblastoma Is So Deadly
Senator John McCain passed away recently after battling brain cancer. Most forms of brain cancer are aggressive and difficult to treat because medications...
SEP 26, 2018
Cancer
SEP 26, 2018
Rare Cancer the Focus of Mesothelioma Awareness Day
More than 2,500 Americans are diagnosed with mesothelioma cancer each year. The cancer is rare but very serious - most patients diagnosed with the disease live just a short 12 to 21 months....
OCT 31, 2018
Drug Discovery
OCT 31, 2018
New Drug Target For a Rare Lymphoma
The promise of immunotherapy in oncology is stronger than ever. Now, an international team of scientists and physicians from the Research Institute of the ...
NOV 14, 2018
Immunology
NOV 14, 2018
Rapid Tumor Targeting
Researchers at the University of California Irvine have developed a technology that will rapidly identify and target T cell receptors for tumor specific antigens...
Loading Comments...